CVS Group earnings 'in line' with guidance as it awaits CMA outcome

CVS Group (AIM:CVSG) reported adjusted EBITDA of approximately £134 million for the year ended June 30, 2025, aligning with market consensus, on revenue of £673.2 million (+5.4%). Growth was supported by continued expansion in Australia, yet UK market conditions remained soft, impacting like-for-like sales and keeping domestic acquisition activity on hold pending the Competition and Markets Authority's investigation outcome, now delayed until September. This indicates a reliance on international growth avenues while regulatory uncertainty and UK market softness persist.

Analysis

CVS Group reported fiscal year 2025 results that met market expectations for adjusted EBITDA at approximately £134 million, but a closer look reveals significant underlying challenges. The 5.4% rise in revenue to £673.2 million was almost entirely driven by acquisitions, primarily in Australia, where the company invested £29.2 million to add 15 practice sites. This inorganic growth masks a nearly stagnant core business, evidenced by a minimal 0.2% increase in like-for-like sales, which the company attributes to soft market conditions in the UK. Compounding this operational weakness is a major regulatory overhang, as UK acquisition activity remains suspended pending a Competition and Markets Authority (CMA) investigation. The recent delay of the CMA's decision until September prolongs this period of uncertainty, effectively freezing the company's domestic growth strategy and increasing its dependency on international M&A for performance.

Key Decisions for Investors

• The primary catalyst for the stock is the September verdict from the UK Competition and Markets Authority; investors should monitor this outcome closely as it will directly impact the company's domestic M&A strategy and future growth profile.
• Focus on the divergence between headline revenue growth and the flat 0.2% like-for-like sales figure, as continued weakness in organic performance would signal deeper issues in the core UK market.
• Evaluate the sustainability of the Australia-focused acquisition strategy, as it currently serves as the primary growth driver while the company faces significant operational and regulatory headwinds in its main UK market.